摘要随着对银屑病发病机制的深入研究,一些更具选择性的靶向不同生物分子的特异性新药相继出现.肿瘤坏死因子-α一直是银屑病治疗的关键靶点,新一代的抗肿瘤坏死因子-α药已研制成功.Th17细胞在银屑病的发生发展中起关键作用,已研制出靶向白介素-23/Th17轴的药物,包括白介素-12/23p40拮抗剂以及白介素-17、白介素-17受体和白介素-22拮抗剂.直接靶向T细胞的药物,如T细胞相关糖蛋白和肽酶以及靶向血管生成、趋化因子受体、神经生长因子和腺苷受体等治疗药已出现.概述目前处于研发阶段或正在进行临床试验的几类不同靶向的抗银屑病新药.

abstractsWith the increased understanding of psoriasis pathogenesis,some new specific biomoleculetargeting drugs with more selectivity have gradually emerged.Tumor necrosis factor-α has been a key target for the treatment of psoriasis,and new-generation agents targeting TNF-α have been successfully developed.T helper type 17 (Th17) cells play a critical role in the initiation and progression of psoriasis.Agents targeting the interleukin (IL)-23/Th17 axis,including antagonists of IL-12/23p40,IL-17,IL-17 receptor and IL-22,have also been available.In addition,new drugs directly targeting T cell-related glycoproteins and enzymes,angiogenesis,chemokine receptors,nerve growth factors and adenosine receptors have been developed.This article describes several types of new targeted anti-psoriatic agents under development or clinical investigations.